{"id":167,"date":"2011-07-19T13:13:08","date_gmt":"2011-07-19T18:13:08","guid":{"rendered":"http:\/\/www.wilsonpr.com\/?p=167"},"modified":"2011-07-19T13:13:08","modified_gmt":"2011-07-19T18:13:08","slug":"p2d-bioscience-receives-nih-funding-to-develop-drugs-for-lung-disease","status":"publish","type":"post","link":"https:\/\/www.wilsonpr.com\/?p=167","title":{"rendered":"P2D Bioscience Receives NIH Funding to Develop Drugs for Lung Disease"},"content":{"rendered":"<p><a href=\"http:\/\/ctt.marketwire.com\/?release=779228&amp;id=541855&amp;type=1&amp;url=http%3a%2f%2fwww.p2dinc.com%2f\"><a href=\"http:\/\/www.p2dinc.com\"><img decoding=\"async\" loading=\"lazy\" class=\"alignleft size-medium wp-image-155\" title=\"P2D logonoline-2\" src=\"http:\/\/www.wilsonpr.com\/wp-content\/uploads\/2011\/04\/P2D-logonoline-2-300x83.jpg\" alt=\"\" width=\"300\" height=\"83\" srcset=\"https:\/\/www.wilsonpr.com\/wp-content\/uploads\/2011\/04\/P2D-logonoline-2-300x83.jpg 300w, https:\/\/www.wilsonpr.com\/wp-content\/uploads\/2011\/04\/P2D-logonoline-2.jpg 404w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/a>P2D Bioscience<\/a> has received a $320,000 grant from the U.S. National Heart,  Lung and Blood Institute. The purpose of this grant is to develop a  novel class of anti-inflammatory drugs specifically targeting lung  diseases, including acute lung injury\/acute respiratory distress  syndrome, chronic obstructive pulmonary disease (COPD) and asthma.<\/p>\n<p><a href=\"http:\/\/www.marketwire.com\/press-release\/P2D-Bioscience-Receives-NIH-Funding-to-Develop-Drugs-for-Lung-Disease-1539778.htm\" target=\"_blank\">Click here<\/a> to read the entire release.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>P2D Bioscience has received a $320,000 grant from the U.S. National Heart, Lung and Blood Institute. The purpose of this grant is to develop a novel class of anti-inflammatory drugs specifically targeting lung diseases, including acute lung injury\/acute respiratory distress syndrome, chronic obstructive pulmonary disease (COPD) and asthma. Click here to read the entire release.<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[56,60,59,57],"_links":{"self":[{"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=\/wp\/v2\/posts\/167"}],"collection":[{"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=167"}],"version-history":[{"count":1,"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=\/wp\/v2\/posts\/167\/revisions"}],"predecessor-version":[{"id":168,"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=\/wp\/v2\/posts\/167\/revisions\/168"}],"wp:attachment":[{"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=167"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=167"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}